Damora Therapeutics (DMRA) Share-based Compensation (2020 - 2026)
Damora Therapeutics (DMRA) posted Share-based Compensation of $8.1 million for Q1 2026, up 1580.75% on a QoQ basis from $483000.0 in Q4 2025, and up 4435.2% year-over-year from $179000.0 in Q1 2025.
Damora Therapeutics (DMRA) Share-based Compensation (2020 - 2026) Analysis & Trends
Damora Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $8.1 million for Q1 2026.
- Quarterly Share-based Compensation rose 4435.2% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 334.77% YoY) and the FY2025 annual result came in at $15.5 million, up 378.54% from the prior year.
- Share-based Compensation was $8.1 million for Q1 2026 at Damora Therapeutics, up from $483000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.1 million in Q1 2026 and bottomed at $172000.0 in Q2 2025.
- A 5-year average of $1.4 million and a median of $1.3 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation slumped 86.83% — and 2026, when it soared 4435.2%.
- Damora Therapeutics' Share-based Compensation stood at $1.3 million in 2022, then decreased by 19.2% to $1.1 million in 2023, then plunged by 71.74% to $308000.0 in 2024, then jumped by 56.82% to $483000.0 in 2025, then surged by 1580.75% to $8.1 million in 2026.
- Business Quant data shows DMRA's Share-based Compensation at $8.1 million in Q1 2026, $483000.0 in Q4 2025, and $904000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 8.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.12 Mn |
| Mar 31, 2026 | 8.12 Mn |
| Dec 31, 2025 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 904,000.00 |
| Sep 30, 2025 | 904,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Mar 31, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |